Biospec

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for use in specific patient populations as determined by clinical guidelines. Currently, there are no detailed indications or usage specifications provided. Healthcare professionals are advised to refer to the latest clinical data and guidelines for appropriate prescribing information. There are no known teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 12 years and older are advised to take 1 teaspoonful (5 ml) every 4 hours, not exceeding 6 doses within a 24-hour period unless otherwise directed by a physician. For children aged 6 years to under 12 years, the recommended dosage is 1/2 teaspoonful (2.5 ml) every 4 hours. Children aged 4 to 6 years should receive 1/4 teaspoonful (1.25 ml) every 4 hours. It is important to consult a doctor for children under 4 years of age regarding appropriate dosing.

Contraindications

Use of this product is contraindicated in patients who experience nervousness, dizziness, or sleeplessness. If these symptoms occur, discontinue use and consult a healthcare professional. Additionally, if symptoms do not improve within 7 days or are accompanied by fever, medical advice should be sought. Patients should also stop use and seek medical attention if a cough persists for more than 7 days, recurs, or is associated with fever, rash, or a persistent headache, as these may indicate a serious underlying condition.

Warnings and Precautions

Patients should adhere strictly to the recommended dosage to avoid potential adverse effects. It is imperative that this product not be used concurrently with prescription monoamine oxidase inhibitors (MAOIs), which are medications prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. Additionally, this product should not be taken for at least two weeks following the discontinuation of an MAOI. If there is uncertainty regarding the presence of an MAOI in any current prescription medication, patients are advised to consult their healthcare provider or pharmacist prior to use.

Healthcare professionals should exercise caution and recommend that patients seek medical advice before using this product if they experience a cough that is productive of excessive phlegm (mucus), or if the cough is persistent, particularly in individuals with a history of smoking, asthma, chronic bronchitis, or emphysema. Such symptoms may require further evaluation and management.

Patients should be instructed to discontinue use and contact their healthcare provider if they experience symptoms such as nervousness, dizziness, or insomnia. Additionally, if symptoms do not improve within seven days, or if they are accompanied by fever, it is essential to seek medical attention. A cough that persists beyond seven days, recurs, or is associated with fever, rash, or a persistent headache may indicate a more serious underlying condition and warrants immediate medical evaluation.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this product. It is crucial not to exceed the recommended dosage, as doing so may lead to serious complications. Additionally, this product should not be used in conjunction with prescription monoamine oxidase inhibitors (MAOIs), which are medications prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. Patients must refrain from using this product for at least two weeks after discontinuing an MAOI. If there is uncertainty regarding the presence of an MAOI in any current prescription medication, patients are advised to consult their doctor or pharmacist prior to use.

Before using this product, patients should seek medical advice if they experience a cough that is accompanied by excessive phlegm (mucus), or if the cough persists or is associated with smoking, asthma, chronic bronchitis, or emphysema. These conditions may require specific medical evaluation and intervention.

Drug Interactions

The concomitant use of this product with monoamine oxidase inhibitors (MAOIs) is contraindicated. MAOIs are typically prescribed for the treatment of depression, certain psychiatric conditions, or Parkinson’s disease. Patients should not initiate treatment with this product if they are currently taking an MAOI or have taken one within the past two weeks.

It is essential for patients to consult with their healthcare provider or pharmacist to confirm whether they are using any prescription medications that contain an MAOI prior to starting this product. This precaution is critical to avoid potential serious interactions that may arise from the combination of these agents.

Packaging & NDC

Below are the non-prescription pack sizes of Biospec (dextromethorphan, guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 12 years and older may be administered 1 teaspoonful (5 mL) every 4 hours. For children aged 6 years to under 12 years, the recommended dosage is 1/2 teaspoonful (2.5 mL) every 4 hours. In children aged 4 to 6 years, the dosage is 1/4 teaspoonful (1.25 mL) every 4 hours. For children under 4 years of age, it is advised to consult a doctor before administration.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure the safety of both the mother and the developing fetus.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

Exceeding the recommended dosage of the medication can lead to serious health consequences. Healthcare professionals are advised to monitor patients closely for any signs of overdosage and to educate patients on the importance of adhering to prescribed dosages.

In the event of suspected overdosage, it is crucial to assess the patient for potential symptoms, which may vary depending on the specific medication involved. Common symptoms of overdosage may include, but are not limited to, gastrointestinal disturbances, neurological effects, and cardiovascular complications.

Management of overdosage should be initiated promptly. Healthcare providers should consider the following steps:

1. Immediate Assessment: Evaluate the patient's clinical status, including vital signs and level of consciousness.

2. Supportive Care: Provide symptomatic treatment as necessary, which may include intravenous fluids, monitoring of cardiac function, and other supportive measures.

3. Decontamination: If the overdosage is recent, consider gastrointestinal decontamination methods, such as activated charcoal, if appropriate and safe for the patient.

4. Consultation: In cases of severe overdosage or uncertainty regarding management, consultation with a poison control center or a medical toxicologist is recommended.

It is imperative that healthcare professionals remain vigilant and proactive in preventing overdosage by ensuring that patients understand their medication regimen and the importance of adhering to prescribed dosages.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

Postmarketing experience has identified several adverse reactions associated with the use of the product. Reports of nervousness, dizziness, and sleeplessness have been documented during the postmarketing setting. These events were reported voluntarily or through surveillance programs, contributing to the ongoing assessment of the product's safety profile.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion.

Patients should be instructed to stop using the medication and consult a doctor if they experience symptoms such as nervousness, dizziness, or sleeplessness. Additionally, if symptoms do not improve within 7 days or are accompanied by fever, patients should seek medical advice.

It is also important to inform patients that if their cough lasts more than 7 days, returns, or is accompanied by fever, rash, or a persistent headache, they should contact their healthcare provider, as these may be indicative of a serious condition.

Storage and Handling

The product is supplied in packaging that includes specific NDC numbers. It should be stored at room temperature, within the range of 15-30°C (59-86°F).

Healthcare professionals are advised to inspect the product prior to use. The product must not be used if the seal under the cap or the cello-band over the cap is torn, broken, or missing, as this may compromise the integrity of the product.

Additional Clinical Information

The medication is administered orally. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. Additionally, it is important to keep the medication out of reach of children to ensure safety. No further information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Biospec, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)